Long-term Therapeutic Effect of Intravitreal Bevacizumab (Avastin) on Myopic Choroidal Neovascularization.
10.3341/jkos.2011.52.1.34
- Author:
Young Seung SEO
1
;
Moo Hwan CHANG
Author Information
1. Department of Ophthalmology, Dankook University Hospital, Cheonan, Korea. changmh@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Bevacizumab;
Choroidal neovascularization;
Intravitreal injection;
Long-term;
Myopic CNV
- MeSH:
Antibodies, Monoclonal, Humanized;
Choroid;
Choroidal Neovascularization;
Fluorescein Angiography;
Humans;
Intravitreal Injections;
Medical Records;
Retrospective Studies;
Tomography, Optical Coherence;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2011;52(1):34-40
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the long-term therapeutic effects of intravitreal bevacizumab on myopic choroidal neovascularization (CNV). METHODS: Medical records of 6 patients who underwent intravitreal bevacizumab injection for myopic CNV and were followed for more than 2 years, were retrospectively investigated. The best corrected visual acuity was compared at 1,3,12, and 24 months after injection. Two years after the injection, a fluorescein angiography and optical coherence tomography (OCT) were performed to evaluate the central macular thickness and leakage of CNV. RESULTS: The mean best corrected visual acuity was 1.16 +/- 0.43 (logMAR), 0.45 +/- 0.21 (logMAR), 0.29 +/- 0.23 (logMAR), 0.14 +/- 0.11 (logMAR), and 0.11 +/- 0.06 (logMAR) at baseline, 1, 3, 12, and 24 months after injection, respectively. CONCLUSIONS: Intravitreal bevacizumab injection for the treatment of myopic CNV was effective in maintaining postoperative visual acuity for 2 years.
